We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 136

Federal court rejects PMPRB Copaxone decision on excessive prices again

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second

Authorized generics in the hypothetical world of generic damages

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada, as in other jurisdictions, links drug marketing approval with patent rights. Innovative drug manufacturers may list relevant patents against

A balancing act: innovation and the regulatory-approval exemption

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

In the pharmaceutical sector, patent systems are concerned with balancing the interests of innovator drug companies, the public and generic

Utility, sound prediction and promise of the patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

In recent years, attacks on the lack of sound prediction and failure to meet the promise of the patent have proven to be a crushing hammer in the

Generic ordered to pay $1.7 million in accounting of profits

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

On March 12, 2013, the Federal Court released its decision in Apotex Inc. v. H. Lundbeck AS, 2013 FC 192. The Court dismissed Apotex's action to

Double-patenting challenges for life sciences companies

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Perhaps more than any other technology field, patentees in the life sciences sector tend to be holders of patent families: collections of patents and

Patents and Canadian competition laws

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 22 2013

In Canada, the Competition Act largely defers to the Patent Act. For example, the Act's abuse of dominance provision (s. 79 Canada's

The Supreme Court of Canada holds Pfizer’s Viagra patent invalid

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

In a cautionary tale to be heeded by patent drafters, the Supreme Court of Canada held that Pfizer's patent directed to sildenafil, better known as

Time for change? Potential impact of Canada’s trade negotiations on pharma patents

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this

An end to generic claims for innovator profits?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Until January 2013, the law of generic claims under section 8 of the Patent Medicines (Notice of Compliance) Regulations (the "NOC Regulations"

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy